Rui Almeida
Rui Almeida has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Rui Caetano Oliveira
Centro de Investigação em Meio Ambiente, Genética e Oncobiologia—CIMAGO, Faculdade de Medicina, Universidade de Coimbra, 3004-535 Coimbra, Portugal
5 shared publications - Paulo Teixeira
Pathology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
4 shared publications - Antero José Abrunhosa
Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal
2 shared publications - Célia Gomes
Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal
2 shared publications - Hugo Ferreira
Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal
2 shared publications - José Manuel Casanova
Center of Investigation in Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
2 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by AME Publishing Company in Journal of Spine Surgery
- Vol. 11 (4) , 922-959
L1 vertebral body replacement using 3D-printed polylactic acid bioimplants: in vitro cellular evaluation, in vivo rat model assessment, and histological analysis of implant osseointegration
Original Article L1 vertebral body replacement using 3D-printed polylactic acid bioimplants: in vitro cellular evaluation, in vivo rat model assessment, and histological analysis of implant osseointegration Diogo Lino Moura, Diogo Casal, Rodrigo Reis, Luís Gonçalves, Sara Alves, Dora Pinto, Manuela Novo, Guilherme Fontinha, Rui Almeida, Pedro Gameiro Santos, João B. Lago, Gabriela Rodrigues, Maria Helena Casimiro, Luís M. Ferreira, João Paulo Leal, Pedro M. P. Santos, Diogo Pais, José Casanova, António Bernardes
- 1 December 2025
- Published by AME Publishing Company in Journal of Spine Surgery
- Vol. 11 (4) , 922-959
Open AccessL1 vertebral body replacement using 3D-printed polylactic acid bioimplants: in vitro cellular evaluation, in vivo rat model assessment, and histological analysis of implant osseointegration
Original Article L1 vertebral body replacement using 3D-printed polylactic acid bioimplants: in vitro cellular evaluation, in vivo rat model assessment, and histological analysis of implant osseointegration Diogo Lino Moura, Diogo Casal, Rodrigo Reis, Luís Gonçalves, Sara Alves, Dora Pinto, Manuela Novo, Guilherme Fontinha, Rui Almeida, Pedro Gameiro Santos, João B. Lago, Gabriela Rodrigues, Maria Helena Casimiro, Luís M. Ferreira, João Paulo Leal, Pedro M. P. Santos, Diogo Pais, José Casanova, António Bernardes
- Open Access
- 12 March 2025
- Published by Springer Nature in Research Square
177Lu-Trastuzumab Radionuclide Therapy: an Effective Approach for Resistant Brain Metastases in HER2+ Breast Cancer
Purpose Breast cancer (BC) is the most common malignancy in women, with HER2 amplification present in 25–30% of metastatic cases. Although HER2-targeted therapies like trastuzumab have significantly improved patient outcomes, their efficacy in HER2 + brain metastases (BrM) is hindered by the emergence of resistance mechanisms. This study explores the therapeutic potential of trastuzumab radiolabeled with the β⁻-emitting radionuclide ¹⁷⁷Lu as a strategy to overcome resistance in HER2 + BrM. Material and methods HER2 + BC cell lines and their brain-tropic derivatives were assessed for HER2 expression and sensitivity to trastuzumab and [177Lu]Lu-DOTA-Trastuzumab. In vivo models were established by orthotopic implantation of HER2 + BC cells for primary tumor formation or intracardiac injection to induce BrM. Once tumors were established, the therapeutic efficacy of trastuzumab and [¹⁷⁷Lu]Lu-DOTA-Trastuzumab was evaluated by monitoring tumor progression via magnetic resonance imaging (MRI). [⁸⁹Zr]Zr-DFO-Trastuzumab PET imaging was performed to assess HER2 expression, while blood-brain barrier (BBB) permeability was evaluated using dynamic contrast-enhanced MRI. Results Brain-tropic HER2 + cells exhibited trastuzumab resistance despite maintaining HER2 expression. In contrast, [177Lu]Lu-DOTA-trastuzumab induced significant DNA damage and cytotoxicity. PET imaging confirmed specific radiotracer uptake in HER2 + primary tumors and BrM. A single dose of [177Lu]Lu-DOTA-trastuzumab effectively suppressed primary tumor growth and achieved complete BrM remission in 40% of treated animals. Heterogeneous BBB permeability was observed across metastatic lesions, potentially influencing radiotracer uptake and therapeutic efficacy. Conclusion These findings underscore [¹⁷⁷Lu]Lu-DOTA-trastuzumab as a novel therapeutic strategy to overcome trastuzumab resistance in HER2 + BrM, offering a promising approach to improve outcomes in metastatic BC.
- 12 March 2025
- Published by Springer Nature in Research Square
Open Access177Lu-Trastuzumab Radionuclide Therapy: an Effective Approach for Resistant Brain Metastases in HER2+ Breast Cancer
Purpose Breast cancer (BC) is the most common malignancy in women, with HER2 amplification present in 25–30% of metastatic cases. Although HER2-targeted therapies like trastuzumab have significantly improved patient outcomes, their efficacy in HER2 + brain metastases (BrM) is hindered by the emergence of resistance mechanisms. This study explores the therapeutic potential of trastuzumab radiolabeled with the β⁻-emitting radionuclide ¹⁷⁷Lu as a strategy to overcome resistance in HER2 + BrM. Material and methods HER2 + BC cell lines and their brain-tropic derivatives were assessed for HER2 expression and sensitivity to trastuzumab and [177Lu]Lu-DOTA-Trastuzumab. In vivo models were established by orthotopic implantation of HER2 + BC cells for primary tumor formation or intracardiac injection to induce BrM. Once tumors were established, the therapeutic efficacy of trastuzumab and [¹⁷⁷Lu]Lu-DOTA-Trastuzumab was evaluated by monitoring tumor progression via magnetic resonance imaging (MRI). [⁸⁹Zr]Zr-DFO-Trastuzumab PET imaging was performed to assess HER2 expression, while blood-brain barrier (BBB) permeability was evaluated using dynamic contrast-enhanced MRI. Results Brain-tropic HER2 + cells exhibited trastuzumab resistance despite maintaining HER2 expression. In contrast, [177Lu]Lu-DOTA-trastuzumab induced significant DNA damage and cytotoxicity. PET imaging confirmed specific radiotracer uptake in HER2 + primary tumors and BrM. A single dose of [177Lu]Lu-DOTA-trastuzumab effectively suppressed primary tumor growth and achieved complete BrM remission in 40% of treated animals. Heterogeneous BBB permeability was observed across metastatic lesions, potentially influencing radiotracer uptake and therapeutic efficacy. Conclusion These findings underscore [¹⁷⁷Lu]Lu-DOTA-trastuzumab as a novel therapeutic strategy to overcome trastuzumab resistance in HER2 + BrM, offering a promising approach to improve outcomes in metastatic BC.
- Open Access
- 30 August 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (1) , 167-183
ENPP1 induces blood–brain barrier dysfunction and promotes brain metastasis formation in human epidermal growth factor receptor 2-positive breast cancer
Background: Brain metastasis (BrM) is a devastating end-stage neurological complication that occurs in up to 50% of human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients. Understanding how disseminating tumor cells manage to cross the blood–brain barrier (BBB) is essential for developing effective preventive strategies. We identified the ecto-nucleotidase ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) as specifically enriched in the secretome of HER2+ brain metastatic cells, prompting us to explore its impact on BBB dysfunction and BrM formation. Methods: We used in vitro BBB and in vivo premetastatic mouse models to evaluate the effect of tumor-secreted ENPP1 on brain vascular permeability. BBB integrity was analyzed by real-time fluorescence imaging of 20 kDa Cy7.5-dextran extravasation and immunofluorescence staining of adherens and tight junction proteins. Pro-metastatic effects of ENPP1 were evaluated in an experimental brain metastatic model. Results: Systemically secreted ENPP1 from primary breast tumors impaired the integrity of BBB with loss of tight and adherens junction proteins early before the onset of BrM. Mechanistically, ENPP1 induced endothelial cell dysfunction by impairing insulin signaling and its downstream AKT/GSK3β/β-catenin pathway. Genetic ablation of ENPP1 from HER2+ brain metastatic cells prevented endothelial cell dysfunction and reduced metastatic burden while prolonging the overall and metastasis-free survival of mice. Furthermore, plasmatic ENPP1 levels correlate with brain metastatic burden and inversely with overall survival. Conclusions: We demonstrated that metastatic BC cells exploit the ENPP1 signaling for cell transmigration across the BBB and brain colonization. Our data implicate ENPP1 as a potential biomarker for poor prognosis and early detection of BrM in HER2+ BC.
- 30 August 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (1) , 167-183
Open AccessENPP1 induces blood–brain barrier dysfunction and promotes brain metastasis formation in human epidermal growth factor receptor 2-positive breast cancer
Background: Brain metastasis (BrM) is a devastating end-stage neurological complication that occurs in up to 50% of human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients. Understanding how disseminating tumor cells manage to cross the blood–brain barrier (BBB) is essential for developing effective preventive strategies. We identified the ecto-nucleotidase ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) as specifically enriched in the secretome of HER2+ brain metastatic cells, prompting us to explore its impact on BBB dysfunction and BrM formation. Methods: We used in vitro BBB and in vivo premetastatic mouse models to evaluate the effect of tumor-secreted ENPP1 on brain vascular permeability. BBB integrity was analyzed by real-time fluorescence imaging of 20 kDa Cy7.5-dextran extravasation and immunofluorescence staining of adherens and tight junction proteins. Pro-metastatic effects of ENPP1 were evaluated in an experimental brain metastatic model. Results: Systemically secreted ENPP1 from primary breast tumors impaired the integrity of BBB with loss of tight and adherens junction proteins early before the onset of BrM. Mechanistically, ENPP1 induced endothelial cell dysfunction by impairing insulin signaling and its downstream AKT/GSK3β/β-catenin pathway. Genetic ablation of ENPP1 from HER2+ brain metastatic cells prevented endothelial cell dysfunction and reduced metastatic burden while prolonging the overall and metastasis-free survival of mice. Furthermore, plasmatic ENPP1 levels correlate with brain metastatic burden and inversely with overall survival. Conclusions: We demonstrated that metastatic BC cells exploit the ENPP1 signaling for cell transmigration across the BBB and brain colonization. Our data implicate ENPP1 as a potential biomarker for poor prognosis and early detection of BrM in HER2+ BC.
- Open Access
- 8 January 2024
- Published by MDPI AG in Journal of Vascular Diseases
- Vol. 3 (1) , 34-48
When Vessels and Sarcomas Combine: A Review of the Inferior Vena Cava Leiomyosarcoma
Leiomyosarcomas (LMSs) are malignant neoplasms of soft muscle differentiation that can be classified into five distinct groups according to site-related origin: intra-abdominal, subcutaneous or deep soft tissue of the limbs, cutaneous, external genitalia, and vascular. This distinction reflects different biological behaviors as well as molecular changes, thus reflecting different prognoses and therapeutic options. Vascular LMSs are the least frequent, arising from the walls of the blood vessels, most commonly from the inferior vena cava. Due to its deep location, symptoms are non-specific, and the disease presents at an advanced stage, sometimes with metastases. Surgery is the treatment of choice, associated with chemo- and radiotherapy. Due to its rarity, most departments have minimal experience handling this disease. This article reviews the current knowledge on vascular leiomyosarcomas, particularly the inferior vena cava leiomyosarcoma.
- 8 January 2024
- Published by MDPI AG in Journal of Vascular Diseases
- Vol. 3 (1) , 34-48
Open AccessWhen Vessels and Sarcomas Combine: A Review of the Inferior Vena Cava Leiomyosarcoma
Leiomyosarcomas (LMSs) are malignant neoplasms of soft muscle differentiation that can be classified into five distinct groups according to site-related origin: intra-abdominal, subcutaneous or deep soft tissue of the limbs, cutaneous, external genitalia, and vascular. This distinction reflects different biological behaviors as well as molecular changes, thus reflecting different prognoses and therapeutic options. Vascular LMSs are the least frequent, arising from the walls of the blood vessels, most commonly from the inferior vena cava. Due to its deep location, symptoms are non-specific, and the disease presents at an advanced stage, sometimes with metastases. Surgery is the treatment of choice, associated with chemo- and radiotherapy. Due to its rarity, most departments have minimal experience handling this disease. This article reviews the current knowledge on vascular leiomyosarcomas, particularly the inferior vena cava leiomyosarcoma.
- 14 May 2023
- Published by Springer Nature
- p. 24-33
Evaluating Rotation Invariant Strategies for Mitosis Detection Through YOLO Algorithms
- 14 May 2023
- Published by Springer Nature
- p. 24-33
Evaluating Rotation Invariant Strategies for Mitosis Detection Through YOLO Algorithms
- Open Access
- 17 April 2022
- Published by Knowledge E DMCC in International Journal of Hematology-Oncology and Stem Cell Research
- Vol. 16 (2) , 94-102
Clinical and Pathological Features of Double-Hit and Triple-Hit High-Grade B-Cell Lymphomas: A Retrospective Study from Three Portuguese Tertiary Centers
Background: High-grade B-cell lymphoma (HGBL) with rearrangements of MYC and BCL2 and/or BCL6, called double and triple-hit lymphomas (DTH-HGBL), are lymphoid malignancies with inferior outcomes when treated with standard chemotherapy. The identification of DTH-HGBL cases is challenging, considering their variable clinical, morphologic, and immunohistochemical features. Materials and Methods: Retrospective revision of medical data of patients diagnosed with DTH-HGBL confirmed by FISH, between January 2010 and January 2020, in three Tertiary Portuguese Hospitals (Coimbra Hospital and University Center, Portuguese Oncology Institute – Coimbra and Portuguese Oncology Institute – Porto). Pathological features, morphology, and immunohistochemical profile were evaluated by at least two experienced pathologists in hematopoietic and lymphoid neoplasms. Results: The cohort included 24 patients: 33.3% triple-hit, 58.3%, MYC/BCL2 double-hit and 8.3% MYC/BCL6 double-hit. There was no gender predominance, with a median age of 62.5±14.3y, 33.3% were diagnosed as nodal disease, and 66.7% as extranodal. Morphologic features of DLBCL were present in 50% of cases, morphological features of both DLBCL and Burkitt lymphoma (DLBCL/BL) in 45.8% and 4.2% of blastoid morphology. Immunohistochemical evaluation, regarding the Hans algorithm, revealed a Germinal center (GC)/GC-like subtype in 83.3% of cases and a non-GC/non-GC-like subtype in 16.7%. MYC was positive in 42.9% and the median proliferative index was 80±12.4%. Conclusion: DTH-HGBL has a very broad range of features. We consider that a cost-effective approach would be to perform cytogenetic analysis in DLBCL and DLBCL/BL cases with GC/GC-like subtype. MYC and BCL2 immunohistochemistry can be useful to identify patients who may benefit from more aggressive therapies, but not as tools for case selection for FISH.
- 17 April 2022
- Published by Knowledge E DMCC in International Journal of Hematology-Oncology and Stem Cell Research
- Vol. 16 (2) , 94-102
Open AccessClinical and Pathological Features of Double-Hit and Triple-Hit High-Grade B-Cell Lymphomas: A Retrospective Study from Three Portuguese Tertiary Centers
Background: High-grade B-cell lymphoma (HGBL) with rearrangements of MYC and BCL2 and/or BCL6, called double and triple-hit lymphomas (DTH-HGBL), are lymphoid malignancies with inferior outcomes when treated with standard chemotherapy. The identification of DTH-HGBL cases is challenging, considering their variable clinical, morphologic, and immunohistochemical features. Materials and Methods: Retrospective revision of medical data of patients diagnosed with DTH-HGBL confirmed by FISH, between January 2010 and January 2020, in three Tertiary Portuguese Hospitals (Coimbra Hospital and University Center, Portuguese Oncology Institute – Coimbra and Portuguese Oncology Institute – Porto). Pathological features, morphology, and immunohistochemical profile were evaluated by at least two experienced pathologists in hematopoietic and lymphoid neoplasms. Results: The cohort included 24 patients: 33.3% triple-hit, 58.3%, MYC/BCL2 double-hit and 8.3% MYC/BCL6 double-hit. There was no gender predominance, with a median age of 62.5±14.3y, 33.3% were diagnosed as nodal disease, and 66.7% as extranodal. Morphologic features of DLBCL were present in 50% of cases, morphological features of both DLBCL and Burkitt lymphoma (DLBCL/BL) in 45.8% and 4.2% of blastoid morphology. Immunohistochemical evaluation, regarding the Hans algorithm, revealed a Germinal center (GC)/GC-like subtype in 83.3% of cases and a non-GC/non-GC-like subtype in 16.7%. MYC was positive in 42.9% and the median proliferative index was 80±12.4%. Conclusion: DTH-HGBL has a very broad range of features. We consider that a cost-effective approach would be to perform cytogenetic analysis in DLBCL and DLBCL/BL cases with GC/GC-like subtype. MYC and BCL2 immunohistochemistry can be useful to identify patients who may benefit from more aggressive therapies, but not as tools for case selection for FISH.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Rare Tumors
- Vol. 13
Histological scores and tumor size on stage II in adrenocortical carcinomas
Adrenocortical carcinomas (ACC) are aggressive tumors with a poor prognosis. Histological scores are advised for the diagnosis, however, there are borderline cases that may be misjudged as adrenocortical adenomas (ACA). The three main scores used are: Weiss Modified System (WMS), Reticulin Algorithm (RA), and Helsinki Score (HS). We intend to compare the accuracy of the three scores in ACC diagnosis and to identify predictive factors of overall survival (OS). Retrospective study (2004–2016) at Centro Hospitalar e Universitário de Coimbra of the adrenal tumors, classified as ACC or ACA, with a history of posterior tumor relapse/metastases, without lesions in the contralateral adrenal gland: 13F and 6M, with a median age of 51 ± 12.41 years. Nodules’ median size was 9.20 ± 6.2 cm. Patients had a median OS of 52 ± 18.6 months, with 57.9% and 46.3%, at 3 and 5 years. Seven patients had local recurrence and nine had metastases. Thirteen cases were in stage II. The WMS and the HS allowed a diagnosis of ACC in 15 cases and the RA defined ACC in 17 cases. All cases had, at least, focal disruption of the reticulin framework. More than 5 mitosis/50 HPF was associated with worse OS: 49.67 ± 21.43 versus 108.86 ± 14.02 months (p = 0.026). In patients with stage II, tumor size ⩾10 cm was associated with worse OS: 19.25 ± 7.15 versus 96.11 ± 16.7 months (p = 0.007), confirmed by multivariate analysis (p = 0.031). The correct diagnosis of ACC is a pathologist responsibility. The RA seems the most accurate. Any loss of the reticulin framework should raise awareness for malignancy. In patients on stage II, a size ⩾10 cm is a predictor of worse prognosis.
- 1 January 2021
- Published by SAGE Publications in Rare Tumors
- Vol. 13
Open AccessHistological scores and tumor size on stage II in adrenocortical carcinomas
Adrenocortical carcinomas (ACC) are aggressive tumors with a poor prognosis. Histological scores are advised for the diagnosis, however, there are borderline cases that may be misjudged as adrenocortical adenomas (ACA). The three main scores used are: Weiss Modified System (WMS), Reticulin Algorithm (RA), and Helsinki Score (HS). We intend to compare the accuracy of the three scores in ACC diagnosis and to identify predictive factors of overall survival (OS). Retrospective study (2004–2016) at Centro Hospitalar e Universitário de Coimbra of the adrenal tumors, classified as ACC or ACA, with a history of posterior tumor relapse/metastases, without lesions in the contralateral adrenal gland: 13F and 6M, with a median age of 51 ± 12.41 years. Nodules’ median size was 9.20 ± 6.2 cm. Patients had a median OS of 52 ± 18.6 months, with 57.9% and 46.3%, at 3 and 5 years. Seven patients had local recurrence and nine had metastases. Thirteen cases were in stage II. The WMS and the HS allowed a diagnosis of ACC in 15 cases and the RA defined ACC in 17 cases. All cases had, at least, focal disruption of the reticulin framework. More than 5 mitosis/50 HPF was associated with worse OS: 49.67 ± 21.43 versus 108.86 ± 14.02 months (p = 0.026). In patients with stage II, tumor size ⩾10 cm was associated with worse OS: 19.25 ± 7.15 versus 96.11 ± 16.7 months (p = 0.007), confirmed by multivariate analysis (p = 0.031). The correct diagnosis of ACC is a pathologist responsibility. The RA seems the most accurate. Any loss of the reticulin framework should raise awareness for malignancy. In patients on stage II, a size ⩾10 cm is a predictor of worse prognosis.
- 1 October 2020
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 33 (10) , 708
Revisiting Clinical Autopsies: Lessons to be Taken from the COVID-19 Pandemic
Revisiting Clinical Autopsies: Lessons to be Taken from the COVID-19 Pandemic
- 1 October 2020
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 33 (10) , 708
Revisiting Clinical Autopsies: Lessons to be Taken from the COVID-19 Pandemic
Revisiting Clinical Autopsies: Lessons to be Taken from the COVID-19 Pandemic
- Open Access
- 10 February 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (2) , e234209
Colo-colonic intussusception as the first manifestation of familial adenomatous polyposis – index case
The abdominal ultrasound showed a hypoechogenic mass in the right hypochondrium, corresponding to a colo-colonic intussusception on CT, associated with multiple polyps throughout the whole colon (figure 1A–D). These polyps were confirmed by colonoscopy performed 15 hours after the CT, showing a larger polyp located in the ascending colon (hepatic angle), corresponding to the location of the intussusception detected previously, that was no longer present. The pathological study of two polyps diagnosed tubulovillous adenomas and the genetic study revealed a mutation in the APC gene, compatible with Familial Adenomatous Polyposis (FAP). The patient has undergone prophylactic proctocolectomy and the surgical specimen showed multiple adenomas throughout the colon, with millimetre dimensions. A larger polyp with 30 mm was confirmed in the ascending colon, which had low-grade dysplasia (figure 2A–D).
- 10 February 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (2) , e234209
Open AccessColo-colonic intussusception as the first manifestation of familial adenomatous polyposis – index case
The abdominal ultrasound showed a hypoechogenic mass in the right hypochondrium, corresponding to a colo-colonic intussusception on CT, associated with multiple polyps throughout the whole colon (figure 1A–D). These polyps were confirmed by colonoscopy performed 15 hours after the CT, showing a larger polyp located in the ascending colon (hepatic angle), corresponding to the location of the intussusception detected previously, that was no longer present. The pathological study of two polyps diagnosed tubulovillous adenomas and the genetic study revealed a mutation in the APC gene, compatible with Familial Adenomatous Polyposis (FAP). The patient has undergone prophylactic proctocolectomy and the surgical specimen showed multiple adenomas throughout the colon, with millimetre dimensions. A larger polyp with 30 mm was confirmed in the ascending colon, which had low-grade dysplasia (figure 2A–D).
- 24 August 2017
- Published by Morressier GmbH
Urachal adenocarcinoma: A case report of rare entity